EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study

Janu Thuraiaiyah iD, Rune Häckert Christensen iD, Haidar M Al-Khazali iD, Messoud Ashina iD, Zaza Katsarava iD, Håkan Ashina iD

European Journal of Neurology · 2026-04 · 33 (4)

DOI: 10.1111/ene.70542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 27.03.2026. Verfasst von Janu Thuraiaiyah und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Calcitonin Gene-Related Peptide Receptor Antagonists, Disability Evaluation, Medical Records. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Lundbeck Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Headache diaries are the gold standard for assessing preventive migraine treatments but can be burdensome. The Migraine Disability Assessment (MIDAS) and the six‐item Headache Impact Test (HIT‐6) offer alternatives for monitoring treatment response, though their effectiveness in identifying treatment responders is unclear relative to diary‐based measures. This study evaluated how well MIDAS and HIT‐6 distinguish responders from non‐responders to erenumab, and aimed to determine cut‐off scores that best align with a ≥ 50% reduction in monthly migraine days (MMDs).

Methods

This prospective, open‐label study enrolled adults with migraine who received 140 mg erenumab for 24 weeks. Treatment response was a ≥ 50% reduction in MMDs based on diary data. MIDAS and HIT‐6 were completed at baseline, Week 12, and Week 24. Discriminative ability and optimal cut‐offs were determined using receiver operating characteristic curve analysis.

Results

Among 582 participants, 300 individuals (52%) achieved a ≥ 50% reduction in MMDs. MIDAS and HIT‐6 demonstrated fair discriminative ability in identifying treatment responders, with area under the curve values ranging from 0.71 to 0.77. The optimal MIDAS cut‐offs were either a 16‐point absolute reduction (78% sensitivity, 60% specificity) or a 49% relative reduction (82% sensitivity, 64% specificity). For HIT‐6, optimal thresholds included an 8‐point reduction (53% sensitivity, 84% specificity) or a 12% relative reduction (54% sensitivity, 84% specificity). Sensitivity analyses using alternative response definitions confirmed the primary findings.

Conclusions

Although MIDAS and HIT‐6 contribute meaningful information on treatment‐related disability reduction, these retrospective tools lack sufficient precision to replace prospective headache diaries in assessing response to erenumab. Trial Registration NCT04603976

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor AntagonistsDisability EvaluationMedical RecordsMigraine DisordersAdultFemaleHumansMaleMiddle AgedProspective StudiesSurveys and QuestionnairesTreatment Outcome

Stichwörter der Autor:innen

monoclonal antibody treatmentpatient‐reported outcome measuresprecision medicinetreatment response

Substanzen

Antibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonistserenumab

Autor:innen und Institutionen

  • Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Translational Research Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Department of Neurology, Christian Hospital Unna, Unna, Germany.
  • Department of Neurology, University of Duisburg-Essen, Essen, Germany.

ORCID-Profile: Janu Thuraiaiyah, Rune Häckert Christensen, Haidar M Al-Khazali, Messoud Ashina, Zaza Katsarava, Håkan Ashina

Förderung

  • Lundbeck Foundation

Zitieren

APA

Thuraiaiyah, J., Christensen, R. H., Al-Khazali, H. M., Ashina, M., Katsarava, Z., & Ashina, H. (2026). MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70542

Vancouver

Thuraiaiyah J, Christensen RH, Al-Khazali HM, Ashina M, Katsarava Z, Ashina H. MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70542

BibTeX
@article{Thuraiaiyah2026,
  author = {Thuraiaiyah, Janu and Christensen, Rune Häckert and Al-Khazali, Haidar M and Ashina, Messoud and Katsarava, Zaza and Ashina, Håkan},
  title = {MIDAS and HIT‐6 Questionnaires Versus Headache Diaries for Monitoring Treatment Response to Erenumab in Migraine: A REFORM Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/ene.70542}
}
Kostenlos starten →